Re: Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in mCRPC

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

imtesty

Rank: Vice President [?]

Points: 1210 [?]

Votes: 21 Score: 4.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in mCRPC

in response to

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in mCRPC

BearDownAZ

posted on Jul 02, 2021 09:33PM

Does anyone know whether this might also apply to neuroendocrine tumors of the colon?

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply